Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes

Daniel Weisdorf, Michael Bishop, Bernie Dharan, Brian Bolwell, Jean Yves Cahn, Mitchell Cairo, Sergio Giralt, John Klein, Hillard Lazarus, Mark R Litzow, David Marks, Philip McCarthy, Carole Miller, Gustavo Milone, James Russell, Kirk R. Schultz, Jorge Sierra, Peter Wiernik, Armand Keating, Fausto LoberizaCraig Kollman, Mary Horowitz

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

For patients with high-risk or relapsed acute lymphoblastic leukemia (ALL) lacking a related histocompatible donor, autologous (Auto) and unrelated donor (URD) transplantation are available options. We compared outcomes and toxicities in 712 patients with ALL (517 URD, 195 Auto) in first complete remission (CR1) or second complete remission (CR2) who underwent transplantation. All patients were <50 years old, although URD patients were younger (median age, 14 versus 18 years, P < .002). The proportion of patients in CR1 versus CR2 was similar (36% versus 38%, P = .57), but more URD recipients than Auto recipients had high-risk karyotypes (25% versus 13%, P = .003) and white blood cell (WBC) counts ≥50 × 109/L (33% versus 14%, P < .001). Engraftment was similar in URD and Auto recipients. Ex vivo purging delayed but did not prevent engraftment after Auto transplantation. Transplantation-related mortality was higher after URD transplantation (42% ± 8%) than after Auto transplantation (20% ± 12%) in CR1 (P = .004) and also in CR2. Conversely, relapse was more frequent after Auto transplantation in CR1 (Auto, 49% ± 12% versus URD, 14% ± 5%) and CR2 (64% ± 8% versus 25% ± 5%) (P < .0001). These findings showed net similar outcomes for these 2 transplantation choices. Transplantation in CR1 yielded similar 3-year survival rates for URD (51% ± 7%) and Auto (44% ± 12%), as did transplantation in CR2 (40% ± 6% versus 32% ± 9%, respectively). Multivariate regression analysis identified significantly better disease-free survival after the first 6 months in matched URD versus Auto in younger patients, in those in CR2 with CR1 >1 year, WBC <50 × 109/L, performance status ≥90%, and in those who have undergone transplantation since 1995. These comparative data suggest that both matched URD and Auto transplantation can yield extended survival. Although URD transplantation offers substantially better protection against leukemic relapse, improvements in allotransplantation safety and refinements in patient selection are required to better aid treatment decision making for the best overall survival.

Original languageEnglish (US)
Pages (from-to)213-220
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume8
Issue number4
StatePublished - 2002
Externally publishedYes

Fingerprint

Unrelated Donors
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transplantation
Survival
Autologous Transplantation
Patient Selection
Decision Making
Tissue Donors
Safety
Recurrence
Therapeutics

Keywords

  • Acute lymphoblastic leukemia
  • Allogeneic unrelated
  • Autologous
  • Bone marrow transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Weisdorf, D., Bishop, M., Dharan, B., Bolwell, B., Cahn, J. Y., Cairo, M., ... Horowitz, M. (2002). Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes. Biology of Blood and Marrow Transplantation, 8(4), 213-220.

Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia : Comparative toxicity and outcomes. / Weisdorf, Daniel; Bishop, Michael; Dharan, Bernie; Bolwell, Brian; Cahn, Jean Yves; Cairo, Mitchell; Giralt, Sergio; Klein, John; Lazarus, Hillard; Litzow, Mark R; Marks, David; McCarthy, Philip; Miller, Carole; Milone, Gustavo; Russell, James; Schultz, Kirk R.; Sierra, Jorge; Wiernik, Peter; Keating, Armand; Loberiza, Fausto; Kollman, Craig; Horowitz, Mary.

In: Biology of Blood and Marrow Transplantation, Vol. 8, No. 4, 2002, p. 213-220.

Research output: Contribution to journalArticle

Weisdorf, D, Bishop, M, Dharan, B, Bolwell, B, Cahn, JY, Cairo, M, Giralt, S, Klein, J, Lazarus, H, Litzow, MR, Marks, D, McCarthy, P, Miller, C, Milone, G, Russell, J, Schultz, KR, Sierra, J, Wiernik, P, Keating, A, Loberiza, F, Kollman, C & Horowitz, M 2002, 'Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes', Biology of Blood and Marrow Transplantation, vol. 8, no. 4, pp. 213-220.
Weisdorf, Daniel ; Bishop, Michael ; Dharan, Bernie ; Bolwell, Brian ; Cahn, Jean Yves ; Cairo, Mitchell ; Giralt, Sergio ; Klein, John ; Lazarus, Hillard ; Litzow, Mark R ; Marks, David ; McCarthy, Philip ; Miller, Carole ; Milone, Gustavo ; Russell, James ; Schultz, Kirk R. ; Sierra, Jorge ; Wiernik, Peter ; Keating, Armand ; Loberiza, Fausto ; Kollman, Craig ; Horowitz, Mary. / Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia : Comparative toxicity and outcomes. In: Biology of Blood and Marrow Transplantation. 2002 ; Vol. 8, No. 4. pp. 213-220.
@article{a04fc49737a743d2a934e35fc6af621c,
title = "Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes",
abstract = "For patients with high-risk or relapsed acute lymphoblastic leukemia (ALL) lacking a related histocompatible donor, autologous (Auto) and unrelated donor (URD) transplantation are available options. We compared outcomes and toxicities in 712 patients with ALL (517 URD, 195 Auto) in first complete remission (CR1) or second complete remission (CR2) who underwent transplantation. All patients were <50 years old, although URD patients were younger (median age, 14 versus 18 years, P < .002). The proportion of patients in CR1 versus CR2 was similar (36{\%} versus 38{\%}, P = .57), but more URD recipients than Auto recipients had high-risk karyotypes (25{\%} versus 13{\%}, P = .003) and white blood cell (WBC) counts ≥50 × 109/L (33{\%} versus 14{\%}, P < .001). Engraftment was similar in URD and Auto recipients. Ex vivo purging delayed but did not prevent engraftment after Auto transplantation. Transplantation-related mortality was higher after URD transplantation (42{\%} ± 8{\%}) than after Auto transplantation (20{\%} ± 12{\%}) in CR1 (P = .004) and also in CR2. Conversely, relapse was more frequent after Auto transplantation in CR1 (Auto, 49{\%} ± 12{\%} versus URD, 14{\%} ± 5{\%}) and CR2 (64{\%} ± 8{\%} versus 25{\%} ± 5{\%}) (P < .0001). These findings showed net similar outcomes for these 2 transplantation choices. Transplantation in CR1 yielded similar 3-year survival rates for URD (51{\%} ± 7{\%}) and Auto (44{\%} ± 12{\%}), as did transplantation in CR2 (40{\%} ± 6{\%} versus 32{\%} ± 9{\%}, respectively). Multivariate regression analysis identified significantly better disease-free survival after the first 6 months in matched URD versus Auto in younger patients, in those in CR2 with CR1 >1 year, WBC <50 × 109/L, performance status ≥90{\%}, and in those who have undergone transplantation since 1995. These comparative data suggest that both matched URD and Auto transplantation can yield extended survival. Although URD transplantation offers substantially better protection against leukemic relapse, improvements in allotransplantation safety and refinements in patient selection are required to better aid treatment decision making for the best overall survival.",
keywords = "Acute lymphoblastic leukemia, Allogeneic unrelated, Autologous, Bone marrow transplantation",
author = "Daniel Weisdorf and Michael Bishop and Bernie Dharan and Brian Bolwell and Cahn, {Jean Yves} and Mitchell Cairo and Sergio Giralt and John Klein and Hillard Lazarus and Litzow, {Mark R} and David Marks and Philip McCarthy and Carole Miller and Gustavo Milone and James Russell and Schultz, {Kirk R.} and Jorge Sierra and Peter Wiernik and Armand Keating and Fausto Loberiza and Craig Kollman and Mary Horowitz",
year = "2002",
language = "English (US)",
volume = "8",
pages = "213--220",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia

T2 - Comparative toxicity and outcomes

AU - Weisdorf, Daniel

AU - Bishop, Michael

AU - Dharan, Bernie

AU - Bolwell, Brian

AU - Cahn, Jean Yves

AU - Cairo, Mitchell

AU - Giralt, Sergio

AU - Klein, John

AU - Lazarus, Hillard

AU - Litzow, Mark R

AU - Marks, David

AU - McCarthy, Philip

AU - Miller, Carole

AU - Milone, Gustavo

AU - Russell, James

AU - Schultz, Kirk R.

AU - Sierra, Jorge

AU - Wiernik, Peter

AU - Keating, Armand

AU - Loberiza, Fausto

AU - Kollman, Craig

AU - Horowitz, Mary

PY - 2002

Y1 - 2002

N2 - For patients with high-risk or relapsed acute lymphoblastic leukemia (ALL) lacking a related histocompatible donor, autologous (Auto) and unrelated donor (URD) transplantation are available options. We compared outcomes and toxicities in 712 patients with ALL (517 URD, 195 Auto) in first complete remission (CR1) or second complete remission (CR2) who underwent transplantation. All patients were <50 years old, although URD patients were younger (median age, 14 versus 18 years, P < .002). The proportion of patients in CR1 versus CR2 was similar (36% versus 38%, P = .57), but more URD recipients than Auto recipients had high-risk karyotypes (25% versus 13%, P = .003) and white blood cell (WBC) counts ≥50 × 109/L (33% versus 14%, P < .001). Engraftment was similar in URD and Auto recipients. Ex vivo purging delayed but did not prevent engraftment after Auto transplantation. Transplantation-related mortality was higher after URD transplantation (42% ± 8%) than after Auto transplantation (20% ± 12%) in CR1 (P = .004) and also in CR2. Conversely, relapse was more frequent after Auto transplantation in CR1 (Auto, 49% ± 12% versus URD, 14% ± 5%) and CR2 (64% ± 8% versus 25% ± 5%) (P < .0001). These findings showed net similar outcomes for these 2 transplantation choices. Transplantation in CR1 yielded similar 3-year survival rates for URD (51% ± 7%) and Auto (44% ± 12%), as did transplantation in CR2 (40% ± 6% versus 32% ± 9%, respectively). Multivariate regression analysis identified significantly better disease-free survival after the first 6 months in matched URD versus Auto in younger patients, in those in CR2 with CR1 >1 year, WBC <50 × 109/L, performance status ≥90%, and in those who have undergone transplantation since 1995. These comparative data suggest that both matched URD and Auto transplantation can yield extended survival. Although URD transplantation offers substantially better protection against leukemic relapse, improvements in allotransplantation safety and refinements in patient selection are required to better aid treatment decision making for the best overall survival.

AB - For patients with high-risk or relapsed acute lymphoblastic leukemia (ALL) lacking a related histocompatible donor, autologous (Auto) and unrelated donor (URD) transplantation are available options. We compared outcomes and toxicities in 712 patients with ALL (517 URD, 195 Auto) in first complete remission (CR1) or second complete remission (CR2) who underwent transplantation. All patients were <50 years old, although URD patients were younger (median age, 14 versus 18 years, P < .002). The proportion of patients in CR1 versus CR2 was similar (36% versus 38%, P = .57), but more URD recipients than Auto recipients had high-risk karyotypes (25% versus 13%, P = .003) and white blood cell (WBC) counts ≥50 × 109/L (33% versus 14%, P < .001). Engraftment was similar in URD and Auto recipients. Ex vivo purging delayed but did not prevent engraftment after Auto transplantation. Transplantation-related mortality was higher after URD transplantation (42% ± 8%) than after Auto transplantation (20% ± 12%) in CR1 (P = .004) and also in CR2. Conversely, relapse was more frequent after Auto transplantation in CR1 (Auto, 49% ± 12% versus URD, 14% ± 5%) and CR2 (64% ± 8% versus 25% ± 5%) (P < .0001). These findings showed net similar outcomes for these 2 transplantation choices. Transplantation in CR1 yielded similar 3-year survival rates for URD (51% ± 7%) and Auto (44% ± 12%), as did transplantation in CR2 (40% ± 6% versus 32% ± 9%, respectively). Multivariate regression analysis identified significantly better disease-free survival after the first 6 months in matched URD versus Auto in younger patients, in those in CR2 with CR1 >1 year, WBC <50 × 109/L, performance status ≥90%, and in those who have undergone transplantation since 1995. These comparative data suggest that both matched URD and Auto transplantation can yield extended survival. Although URD transplantation offers substantially better protection against leukemic relapse, improvements in allotransplantation safety and refinements in patient selection are required to better aid treatment decision making for the best overall survival.

KW - Acute lymphoblastic leukemia

KW - Allogeneic unrelated

KW - Autologous

KW - Bone marrow transplantation

UR - http://www.scopus.com/inward/record.url?scp=0035999678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035999678&partnerID=8YFLogxK

M3 - Article

C2 - 12014810

AN - SCOPUS:0035999678

VL - 8

SP - 213

EP - 220

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 4

ER -